Dignitana To Exhibit DigniCap® at San Antonio Breast Cancer Symposium

First Scalp Cooling Device to Complete a Formal Trial for U.S. FDA Approval Will Be On Display At Gathering of World’s Leading Breast Cancer Researchers and Physicians This December

Dignitana, a world leader in medical scalp cooling technology, has announced that the scalp cooling system DigniCap®, for the prevention of chemotherapy related hair loss, will be exhibited at the 2015 San Antonio Breast Cancer Symposium (SABCS). One of the world’s most important gatherings of academic and private breast cancer physicians and researchers, SABCS provides state-of-the-art information and updates based on the latest breast cancer medical research and scientific advances.

Scalp cooling devices for the reduction of chemotherapy related alopecia have been in wide use throughout Europe, but no device has yet been cleared for use in the United States. DigniCap® is the only scalp-cooling device to have completed a formal trial for U.S. FDA approval; the device is currently pending FDA Clearance. DigniCap® has been clinically tested with breast cancer patients who received positive results at some of the most renowned medical centers in the U.S.

Scalp cooling is now experiencing increased interest from both doctors and patients. Dignitana’s goal is to continue to raise awareness and knowledge about scalp cooling and DigniCap®. Dignitana will, for the first time, display DigniCap® at the symposium.  

Jan Richardsson, CEO Dignitana AB (publ):

"The time is right to introduce DigniCap® at SABCS to physicians who are eager to provide their patients with an alternative to one of the most distressful side effects of chemotherapy. We are currently in the absolute final stages of the regulatory process for FDA approval in the United States for DigniCap®. I am convinced that DigniCap® will be approved. It has been a long process, but pending the approval we are working hard to establish contacts with potential customers and negotiate contracts with hospitals. We are very eager to bring this important technology to market.”

Media Contact:

Caren Browning                                                                                                           Jan Richardsson

King + Company                                                                                                           Dignitana Chief Executive Officer

00 1 212 561-7464                                                                                                     +46 46 16 30 92

Caren.Browning@kingcompr.com                                                                            Jan.Richardsson@dignitana.se  

About Dignitana AB (publ)
Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bankaktiebolag as Certified Advisor. For more information visit www.dignitana.com

About the scalp cooling system DigniCap®
Dignitana’s core product - DigniCap® - is a patented scalp-cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® is developed to provide continuous cooling with high efficacy, safety and acceptable patient comfort.


About Us

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Stockholm with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank AB, Certified Adviser, +46 (0) 8 463 83 00 certifiedadviser@penser.se www.penser.se Learn more at www.dignitana.se and www.dignicap.com.


Documents & Links


The time is right to introduce DigniCap® at SABCS to physicians who are eager to provide their patients with an alternative to one of the most widely feared side effects of chemotherapy.
Jan Richardsson, CEO Dignitana AB